Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SIGA TechnologiesSIGA +1.57%62 Debt-to-EBITDA is 0.01 as of Jun. 2026, which is at its 10-year median of 0.01. GuruFocus rates SIGA with a GF Score™ of 62/100 and a GF Value™ of $2.55 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 681 Drug Manufacturers companies, SIGA Technologies ranks worse than 146842.73% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SIGA Technologies's Debt-to-EBITDA or its related term are showing as below:
SIGA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.03 Med: 0.01 Max: 13.15
Current: -0.04
During the past 13 years, the highest Debt-to-EBITDA Ratio of SIGA Technologies was 13.15. The lowest was -3.03. And the median was 0.01.
SIGA's Debt-to-EBITDA is ranked worse than 100% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs SIGA: -0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SIGA Technologies Debt-to-EBITDA Related Terms
SIGA Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SIGA Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SIGA vs ANIK, TKNO, DERM: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SIGA Technologies Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SIGA Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
SIGA Technologies (SIGA) has a Debt-to-EBITDA of 0.01 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SIGA Technologies. This is near median its historical median of 0.01. According to the industry distribution chart, SIGA Technologies ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is SIGA Technologies' Debt-to-EBITDA too high?
SIGA Technologies' current Debt-to-EBITDA of 0.01 is near median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. SIGA Technologies' value of 0.01 is 99.4% below this industry median. Based on the distribution chart, SIGA Technologies ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SIGA Technologies has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SIGA Technologies' Debt-to-EBITDA compare to ANIK and TKNO?
According to the Drug Manufacturers industry distribution chart, SIGA Technologies ranks #999999 out of 681 companies for Debt-to-EBITDA. This places SIGA Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. SIGA Technologies' value of 0.01 is 99.4% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 1.63, SIGA Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SIGA Technologies's current Debt-to-EBITDA of 0.01 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SIGA Technologies. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SIGA Technologies's current Debt-to-EBITDA is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SIGA Technologies stock overvalued right now?
Based on GuruFocus' analysis, SIGA Technologies (SIGA) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.55, compared to a current price of $2.91 — trading 13.9% above its estimated fair value. The current Debt-to-EBITDA is 0.01, which is near median its 10-year median of 0.01 and 99.4% below the Drug Manufacturers industry median of 1.63. SIGA Technologies' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SIGA Technologies (SIGA), the current Debt-to-EBITDA is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SIGA Technologies (SIGA) Overvalued in 2026?
Based on GuruFocus' analysis, SIGA Technologies stock appears to be overvalued.
The current stock price of $2.91 is trading 13.9% above its estimated GF Value™ of $2.55.
GuruFocus considers SIGA Technologies to be Modestly Overvalued.
Key valuation signals for SIGA:
Debt-to-EBITDA: 0.01 (near median its 10-year median of 0.01)
GF Value™: $2.55 vs. price of $2.91 (13.9% above fair value)
Industry Position: 99.4% below the Drug Manufacturers median (#999999 of 681)
No single metric tells the full story. See the SIGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
62GF Score
Get the complete analysis for SIGA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SIGA has been successfully added to your 
